TRex Bio Inc. (TRexBio) announced an $84m series B venture capital round on 13 November that it will use to develop lead drug candidate TRB-061, a TNFR2 agonist, through early clinical proof-of-concept in patients with inflammatory diseases, including atopic dermatitis and ulcerative colitis. TRexBio plans to initiate a Phase I trial with TRB-061 during the first half of 2025.
Finance Watch: TRexBio Raises $84m To Pursue Proof Of Concept In Inflammatory Diseases
Private Company Edition: TRexBio’s series B venture capital round will fund initial clinical trials for TRB-061, a TNFR2 agonist. And in addition to mega-rounds from Trace, Alentis and Metsera, Evommune and Axonis raised $115m each, while Elektrofi completed a $112.5m series C.
More from Finance Watch
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Public Company Edition: Cargo suspended development and cut 90% of its workforce to focus on strategic alternatives, while Pyxis and Kiromic laid off or furloughed employees. Also, Pfizer sold its remaining Haleon shares for $3.3bn, Galderma sold $1bn in bonds and other financings.
• By
Private Company Edition: There have been five $100m-plus VC rounds so far this month, up from three in all of February. Flagship unveiled Lila Sciences with $200m, while Curevo and Insilico raised $110m in series B and E rounds, respectively. Also, Arbor Biotech garnered $73.9m.
More from Scrip
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy (CGT) space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
• By
In this week's episode: pharma dodges tariffs for now; Marks’s departure from FDA rattles industry; Phase 2b win for AstraZeneca’s oral PCSK9; Hengrui renews global Phase 3 push; and Novo’s new cardio results for semaglutide.